Products Cited in Publications Worldwide Ciclopirox suppresses poxvirus replication by targeting iron metabolism

Ciclopirox suppresses poxvirus replication by targeting iron metabolism

Pant, Anil; Belhaouari, Djamal Brahim; Dsouza, Lara; Udayanga, DM Nirosh; Wang, Zhengqiang; Yang, Zhilong

DOI:

Abstract

Poxviruses remain a significant global health concern, necessitating the development of novel strategies. Through high-throughput screening, we previously identified (CPX), an FDA-approved , as a hit that inhibits vaccinia virus (VACV) replication. Here, we further characterized its activity and mechanism of action using human primary fibroblasts. CPX significantly reduced VACV titers without reducing host cell viability, with an EC50 in the sub-micromolar range and a CC50 >500 μM. Rescue experiments demonstrated that CPX inhibits viral replication primarily through chelation of intracellular Fe3+ and, to a lesser extent, Fe2+, as evidenced by partial restoration of viral replication with ferric ammonium citrate supplementation. Furthermore, overexpression of the iron-dependent enzymes RRM2 and the VACV-encoded F4L reduced the inhibitory effect of CPX, indicating that these host and viral proteins are affected by CPX treatment. Moreover, CPX treatment also suppressed cowpox virus and monkeypox (mpox) virus replication in vitro. It also reduced VACV titers in ex vivo mouse lung tissue. These findings highlight host iron metabolism as a critical determinant of poxvirus replication and support repurposing CPX as a broad-spectrum candidate.

Keywords

; Poxviruses ; Monkeypox Virus ; Mpox ; Iron Metabolism ; Antiviral

Purchased from AmBeed

Deferoxamine Mesylate

A377160138-14-798%

Deferoxamine Mesylate

1133.0/5g

Detail